Description

Lintuzumab is a humanized monoclonal antibody designed for targeted therapeutic applications. Its primary value lies in its specific binding affinity for CD33, a cell surface antigen expressed on myeloid leukemia cells, making it a critical component in advanced oncology research and development. This product is essential for pharmaceutical companies, biotech research institutions, and clinical laboratories focused on hematologic malignancies and antibody-drug conjugate (ADC) platforms. We supply high-purity Lintuzumab CAS NO 166089-32-3 to support global drug discovery and biopharmaceutical manufacturing.

Application

• Targeted Cancer Therapy Development: Primary use in research and development of treatments for acute myeloid leukemia (AML).
• Antibody-Drug Conjugate (ADC) Payload: Serves as the targeting moiety in ADC constructs for precise drug delivery.
• Immunological Research: Used in studies of CD33 antigen biology and myeloid cell signaling pathways.
• Diagnostic Reagent Production: Component in the development of flow cytometry kits and in vitro diagnostic assays.
• Preclinical and Clinical Studies: Critical material for pharmacokinetic, pharmacodynamic, and toxicology evaluations.
• Biopharmaceutical Reference Standard: Acts as a quality control standard for biosimilar and biotherapeutic manufacturing.

Basic Information

Product Name	Lintuzumab
CAS No.	166089-32-3
Molecular Formula	C6440H9916N1704O2016S46
Molecular Weight	Approx. 145 kDa
Synonyms	HuM195; SGN-33; Anti-CD33 Monoclonal Antibody; hP67.6; Monoclonal Antibody HuM195; CD33 Antagonist; Immunoglobulin G1, anti-(human CD33 antigen) (human-mouse monoclonal hP67.6 γ1-chain), disulfide with human-mouse monoclonal hP67.6 κ-chain, dimer
EINECS	Contact for details

Quality Control

Our Lintuzumab is manufactured under strict quality systems to ensure high purity, consistent activity, and low endotoxin levels, suitable for research and development applications. Each batch is supported by a comprehensive Certificate of Analysis (COA) detailing purity, identity, potency, and sterility. While not intended for human administration as supplied, our quality protocols align with principles of cGMP for reliable and reproducible performance in critical workflows.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized material at -20°C or below. Reconstituted solutions should be aliquoted and stored at -80°C to minimize freeze-thaw cycles. This product is hygroscopic (moisture-sensitive) and should be handled in a dry environment. Always use appropriate aseptic techniques when handling.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder
Identification (HPLC/MS)	Conforms to reference standard
Purity (SDS-PAGE)	> 95% (Reduced & Non-reduced)
Purity (SEC-HPLC)	> 98% (Monomer)
Protein Content (UV)	> 1.0 mg/vial
Endotoxin (LAL)	< 1.0 EU/mg
Biological Activity (Binding ELISA)	> 90% relative activity
Sterility (Membrane Filtration)	Sterile

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.